{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:20:17Z","timestamp":1771258817191,"version":"3.50.1"},"reference-count":32,"publisher":"Endocrinology Research Centre","issue":"5","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Donohue syndrome (DS), also called Leprechaunism, is the most severe form of insulin resistance associated with biallelic mutations in INSR gene (OMIM: 147670). The approximate incidence of this syndrome is 1 per 1000000 births. Patients are present with typical clinical features such as intrauterine growth retardation, facial dysmorphism, severe metabolic disturbances, hepatomegaly and hypertrophic cardiomyopathy. Most DS patients die within the first two years of life due to respiratory infections, severe hypoglycemia or progressive cardiomyopathy. Treatment options are limited and no specific therapy exist for DS. Given the similarities between insulin and insulin-like growth factor 1 (IGF-1) receptors, recombinant human IGF-1 (rhIGF-1) has been used to treat severe insulin resistance including DS.<\/jats:p><jats:p>We report the case of a male patient with genetically confirmed Donohue syndrome, successfully treated with continuous subcutaneous IGF1 infusion via insulin pump. We observed improvement of glycemic control, liver function and cardiac hypertrophy regression following 15-month IGF1 therapy.<\/jats:p>","DOI":"10.14341\/probl13121","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:09:50Z","timestamp":1667851790000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":4,"title":["Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-2460","authenticated-orcid":true,"given":"M. A.","family":"Melikyan","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-7673","authenticated-orcid":true,"given":"T. E.","family":"Ivannikova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-5789","authenticated-orcid":true,"given":"N. V.","family":"Milovanova","sequence":"additional","affiliation":[{"name":"Research Centre for medical genetics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-5372","authenticated-orcid":true,"given":"A. A.","family":"Kolodkina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-5732","authenticated-orcid":true,"given":"O. B.","family":"Bezlepkina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-9742","authenticated-orcid":true,"given":"N. G.","family":"Mokryshev\u0430","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45(5):505-519. doi: https:\/\/doi.org\/10.1016\/s0022-3476(54)80113-2","DOI":"10.1016\/S0022-3476(54)80113-2"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Donohue WL. Clinicopathologic Conference at the Hospital for Sick Children. J Pediatr. 1948;32(6):739-748. doi: https:\/\/doi.org\/10.1016\/S0022-3476(48)80231-3","DOI":"10.1016\/S0022-3476(48)80231-3"},{"key":"ref3","unstructured":"Ben Harouch S, Klar A, Falik Zaccai TC. INSR-Related Severe Syndromic Insulin Resistance. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2021 Nov 7]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK476444\/"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Desbois-Mouthon C, Girodon E, Ghanem N, et al. Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families. Prenat Diagn. 1997;17(7):657-663. doi: https:\/\/doi.org\/10.1002\/(SICI)1097-0223(199707)17:7<657::AID-PD132>3.0.CO;2-8","DOI":"10.1002\/(SICI)1097-0223(199707)17:7<657::AID-PD132>3.0.CO;2-8"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Musso C, Cochran E, Moran SA, et al. Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson-Mendenhall Syndromes). Medicine (Baltimore). 2004;83(4):209-222. doi: https:\/\/doi.org\/10.1097\/01.md.0000133625.73570.54","DOI":"10.1097\/01.md.0000133625.73570.54"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Longo N, Wang Y, Smith SA, Langley SD, et al. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002;11(12):1465-1475. doi: https:\/\/doi.org\/10.1093\/hmg\/11.12.146","DOI":"10.1093\/hmg\/11.12.1465"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"George S, Johansen A, Soos MA, et al. Deletion of V335 from the L2 Domain of the Insulin Receptor Results in a Conformationally Abnormal Receptor That Is Unable to Bind Insulin and Causes Donohue\u2019s Syndrome in a Human Subject. Endocrinology. 2003;144(2):631-637. doi: https:\/\/doi.org\/10.1210\/en.2002-220815","DOI":"10.1210\/en.2002-220815"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Riehle C, Abel ED. Insulin Signaling and Heart Failure. Circ Res. 2016;118(7):1151-1169. doi: https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306206","DOI":"10.1161\/CIRCRESAHA.116.306206"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bertrand L, Horman S, Beauloye C, Vanoverschelde J-L. Insulin signalling in the heart. Cardiovasc Res. 2008;79(2):238-248. doi: https:\/\/doi.org\/10.1093\/cvr\/cvn093","DOI":"10.1093\/cvr\/cvn093"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Watson RT, Pessin JE. Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem Sci. 2006;31(4):215-222. doi: https:\/\/doi.org\/10.1016\/j.tibs.2006.02.007","DOI":"10.1016\/j.tibs.2006.02.007"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated Activation of eNOS Is Independent of Ca2+ but Requires Phosphorylation by Akt at Ser1179. J Biol Chem. 2001;276(32):30392-30398. doi: https:\/\/doi.org\/10.1074\/jbc.M103702200","DOI":"10.1074\/jbc.M103702200"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Atabek ME, Pirgon O. Some Effect of Metformin on Insulin Resistance in an Infant with Leprechaunism. J Pediatr Endocrinol Metab. 2006;19(10):30392-30398. doi: https:\/\/doi.org\/10.1515\/JPEM.2006.19.10.1257","DOI":"10.1515\/JPEM.2006.19.10.1257"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Cochran E, Young JR, Sebring N, et al. Efficacy of Recombinant Methionyl Human Leptin Therapy for the Extreme Insulin Resistance of the Rabson-Mendenhall Syndrome. J Clin Endocrinol Metab. 2004;89(4):1548-1554. doi: https:\/\/doi.org\/10.1210\/jc.2003-031952","DOI":"10.1210\/jc.2003-031952"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5(10):2503-2512. doi: https:\/\/doi.org\/10.1002\/j.1460-2075.1986.tb04528.x","DOI":"10.1002\/j.1460-2075.1986.tb04528.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Dupont J, LeRoith D. Insulin and Insulin-Like Growth Factor I Receptors: Similarities and Differences in Signal Transduction. Horm Res Paediatr. 2001;55(S2):22-26. doi: https:\/\/doi.org\/10.1159\/000063469","DOI":"10.1159\/000063469"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Nakae J, Kido Y, Accili D. Distinct and Overlapping Functions of Insulin and IGF-I Receptors. Endocr Rev. 2001;22(6):818-835. doi: https:\/\/doi.org\/10.1210\/edrv.22.6.0452","DOI":"10.1210\/edrv.22.6.0452"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"LeRoith D, Yakar S. Mechanisms of Disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007;3(3):302-310. doi: https:\/\/doi.org\/10.1038\/ncpendmet0427","DOI":"10.1038\/ncpendmet0427"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Moses AC, Young SCJ, Morrow LA, et al. Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes. Diabetes. 1996;45(1):91-100. doi: https:\/\/doi.org\/10.2337\/diab.45.1.91","DOI":"10.2337\/diab.45.1.91"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab. 2005;16(4):190-197. doi: https:\/\/doi.org\/10.1016\/j.tem.2005.03.011","DOI":"10.1016\/j.tem.2005.03.011"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Quin JD, Fisher BM, Paterson KR, et al. Acute Response to Recombinant Insulin-like Growth Factor I in a Patient with Mendenhall\u2019s Syndrome. N Engl J Med. 1990;323(20):1425-1426. doi: https:\/\/doi.org\/10.1056\/NEJM199011153232016","DOI":"10.1056\/NEJM199011153232016"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Schoenle EJ, Zenobi PD, Torresani T, et al. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia. 1991;34(9):675-679. doi: https:\/\/doi.org\/10.1007\/BF00400998","DOI":"10.1007\/BF00400998"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hussain M, Froesch ER. Treatment of type A insulin resistance with insulin-like growth factor-I. Lancet. 1993;341(8859):1536-1537. doi: https:\/\/doi.org\/10.1016\/0140-6736(93)90674-6","DOI":"10.1016\/0140-6736(93)90674-6"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Zenobi PD, Glatz Y, Keller A, et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol. 1994;131(3):251-257. doi: https:\/\/doi.org\/10.1530\/eje.0.1310251","DOI":"10.1530\/eje.0.1310251"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Vestergaard H, Rossen M, Urhammer SA, et al. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol. 1997;136(5):475-482. doi: https:\/\/doi.org\/10.1530\/eje.0.1360475","DOI":"10.1530\/eje.0.1360475"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Morrow LA, O\u2019Brien MB, Moller DE, et al. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab. 1994;79(1):205-210. doi: https:\/\/doi.org\/10.1210\/jcem.79.1.8027228","DOI":"10.1210\/jc.79.1.205"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Nakashima N. Insulin resistance associated with substitution of histidine for arginine 252 in the alpha-subunit of the human insulin receptor: trial of insulin-like growth factor I injection therapy to enhance insulin sensitivity. J Clin Endocrinol Metab. 1995;80(12):3662-3667. doi: https:\/\/doi.org\/10.1210\/jc.80.12.3662","DOI":"10.1210\/jc.80.12.3662"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Longo N, Singh R, Elsas LJ. Decreased half-life of insulin-like growth factor I in Rabson-Mendenhall syndrome. J Inherit Metab Dis. 2001;24(5):546-550. doi: https:\/\/doi.org\/10.1023\/A:1012411709972","DOI":"10.1023\/A:1012411709972"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Weber DR, Stanescu DE, Semple R, et al. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. J Pediatr Endocrinol Metab. 2014;24(5):546-550. doi: https:\/\/doi.org\/10.1515\/jpem-2013-0402","DOI":"10.1515\/jpem-2013-0402"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of Insulinlike Growth Factor I Therapy for Patients With Extreme Insulin Resistance Syndromes. Diabetes. 1993;42(5):696-705. doi: https:\/\/doi.org\/10.2337\/diab.42.5.696","DOI":"10.2337\/diabetes.42.5.696"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"de Kerdanet M, Caron-Debarle M, Nivot S, et al. Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in leprechaunism. Diabetes Metab. 2015;41(4):331-337. doi: https:\/\/doi.org\/10.1016\/j.diabet.2014.11.001","DOI":"10.1016\/j.diabet.2014.11.001"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nobile S, Semple RK, Carnielli VP. A novel mutation of the insulin receptor gene in a preterm infant with Donohue syndrome and heart failure. J Pediatr Endocrinol Metab. 2012;25(3-4). doi: https:\/\/doi.org\/10.1515\/jpem-2011-0448","DOI":"10.1515\/jpem-2011-0448"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Semple RK, Williams RM, Dunger DB. What is the best management strategy for patients with severe insulin resistance? Clin Endocrinol (Oxf). 2010;73(3):286-290. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03810.x","DOI":"10.1111\/j.1365-2265.2010.03810.x"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13121\/10340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T15:29:08Z","timestamp":1668439748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,6]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13121","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}